Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports

Satoshi Okada, Keisuke Hata, Kazushige Kawai, Yoko Yamamoto, Toshiaki Tanaka, Takeshi Nishikawa, Kazuhito Sasaki, Manabu Kaneko, Shigenobu Emoto, Koji Murono, Hiroaki Nozawa, Satoshi Okada, Keisuke Hata, Kazushige Kawai, Yoko Yamamoto, Toshiaki Tanaka, Takeshi Nishikawa, Kazuhito Sasaki, Manabu Kaneko, Shigenobu Emoto, Koji Murono, Hiroaki Nozawa

Abstract

Rationale: The prevalence of anastomotic recurrence (AR) in colorectal cancer (CRC) after resection of the primary tumor (PT) is 5% to 14%. However, no association has been observed between specific somatic genetic alterations and AR. Such associations may shed light on the mechanism of AR.

Patient concerns: We experienced 2 patients with AR of CRC. The first patient was a 42-year-old woman who underwent resection of an AR of rectal cancer 2 times within 19 months after resection of the PT. The second patient was a 77-year-old woman who underwent resection of an AR of ascending colon cancer twice within 38 months after resection of the PT.

Diagnosis: Both cases were diagnosed as repetitive AR.

Interventions: Loss of heterozygosity analysis, microsatellite instability (MSI) study of 9 microsatellite loci, and mutational analysis of KRAS, BRAF, APC, TP53, and SMAD4 were performed.

Outcomes: All the lesions, except 1, harbored mutations in APC, KRAS, and TP53, without MSI, after neoadjuvant chemoradiotherapy. The APC, KRAS, and TP53 mutations were pathogenic or likely pathogenic in the PTs and ARs. Both women harbored the same KRAS G13D mutation, which accounts for 8% of all KRAS mutations in sporadic CRC s. The probability of the incidental occurrence of KRAS G13D mutations in both cases is 0.64%, provided that the mutations were independent of AR.

Lessons: Our findings may shed light on the mechanism of AR in CRC, namely, that the PT harbored the same mutations as the AR and the lesions in both cases harbored the KRAS G13D mutation.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Colonoscopy findings and clinical course of the 2 cases. Case 1: a 42-year-old woman with rectal cancer. Case 2: a 77-year-old woman with ascending colon cancer.

References

    1. Bowne WB, Lee B, Wong WD, et al. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases. Dis Colon Rectum 2005;48:897–909.
    1. Read TE, Mutch MG, Chang BW, et al. Locoregional recurrence and survival after curative resection of adenocarcinoma of the colon. J Am Coll Surg 2002;195:33–40.
    1. de Chaisemartin C, Penna C, Goere D, et al. Presentation and prognosis of local recurrence after total mesorectal excision. Colorectal Dis 2009;11:60–6.
    1. Gopalan S, Bose JC, Periasamy S. Anastomotic recurrence of colon cancer-is it a local recurrence, a second primary, or a metastatic disease (local manifestation of systemic disease). Indian J Surg 2015;77:232–6.
    1. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139:1315–26.
    1. Costi R, Santi C, Bottarelli L, et al. Anastomotic recurrence of colon cancer: genetic analysis challenges the widely held theories of cancerous cells’ intraluminal implantation and metachronous carcinogenesis. J Surg Oncol 2016;114:228–36.
    1. Vakiani E, Shah RH, Berger MF, et al. Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget 2017;8:42487–94.
    1. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196–206.
    1. Watanabe T, Kobunai T, Yamamoto Y, et al. Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol 2012;30:2256–64.
    1. Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017;17:79–92.
    1. Normanno N, Tejpar S, Morgillo F, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519–27.
    1. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–17.
    1. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812–20.
    1. Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012;30:3570–7.
    1. Margonis GA, Kim Y, Spolverato G, et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg 2015;150:722–9.
    1. Margonis GA, Kim Y, Sasaki K, et al. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer 2016;122:2698–707.

Source: PubMed

3
Iratkozz fel